BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 11792884)

  • 1. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis.
    Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik B; Skowronski J; Chwiecko J
    Rheumatology (Oxford); 2002 Jan; 41(1):78-87. PubMed ID: 11792884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Latosiewicz R; Skowronski J; Cylwik JP; Cylwik B; Chwiecko J
    J Rheumatol; 2005 Sep; 32(9):1666-72. PubMed ID: 16142858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.
    Yoshihara Y; Nakamura H; Obata K; Yamada H; Hayakawa T; Fujikawa K; Okada Y
    Ann Rheum Dis; 2000 Jun; 59(6):455-61. PubMed ID: 10834863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
    Goldbach-Mansky R; Lee JM; Hoxworth JM; Smith D; Duray P; Schumacher RH; Yarboro CH; Klippel J; Kleiner D; El-Gabalawy HS
    Arthritis Res; 2000; 2(2):145-53. PubMed ID: 11062605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
    Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A
    J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum cytokines in different histological variants of rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik B; Skowronski J; Chwiecko J
    J Rheumatol; 2001 Jun; 28(6):1211-7. PubMed ID: 11409111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
    Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
    Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis.
    Smeets TJ; Barg EC; Kraan MC; Smith MD; Breedveld FC; Tak PP
    Ann Rheum Dis; 2003 Jul; 62(7):635-8. PubMed ID: 12810425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
    Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
    Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis.
    Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik JP; Cylwik B; Skowronski J; Chwiecko J
    Ann Rheum Dis; 2002 Sep; 61(9):804-9. PubMed ID: 12176805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis.
    Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik JP; Cylwik B; Skowronski J; Chwiecko J
    Clin Exp Rheumatol; 2003; 21(1):63-9. PubMed ID: 12673891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase protein expression profiles cannot distinguish between normal and early osteoarthritic synovial fluid.
    Heard BJ; Martin L; Rattner JB; Frank CB; Hart DA; Krawetz R
    BMC Musculoskelet Disord; 2012 Jul; 13():126. PubMed ID: 22824140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in joint fluid of the patients with loose artificial hip joints.
    Takei I; Takagi M; Santavirta S; Ida H; Hamasaki M; Ishii M; Fukushima S; Ogino T; Konttinen YT
    J Biomed Mater Res; 1999 Jun; 45(3):175-83. PubMed ID: 10397973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10.
    Tolboom TC; Pieterman E; van der Laan WH; Toes RE; Huidekoper AL; Nelissen RG; Breedveld FC; Huizinga TW
    Ann Rheum Dis; 2002 Nov; 61(11):975-80. PubMed ID: 12379519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serum interleukin 6 (il-6A) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis].
    Klimiuk PA; Sierakowski S; Chwiećko J
    Pol Arch Med Wewn; 2003 Feb; 109(2):119-23. PubMed ID: 12879774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis.
    Fiedorczyk M; Klimiuk PA; Sierakowski S; Gindzienska-Sieskiewicz E; Chwiecko J
    J Rheumatol; 2006 Aug; 33(8):1523-9. PubMed ID: 16881109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered gene expression levels of matrix metalloproteinases and their inhibitors in periodontitis-affected gingival tissue.
    Kubota T; Itagaki M; Hoshino C; Nagata M; Morozumi T; Kobayashi T; Takagi R; Yoshie H
    J Periodontol; 2008 Jan; 79(1):166-73. PubMed ID: 18166107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis.
    Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik JP; Cylwik B; Skowronski J; Chwiecko J
    Ann Rheum Dis; 2003 May; 62(5):472-5. PubMed ID: 12695163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.